-

10:13:22 AM

NUVB Stock News

NUVB - Nuvation Bio Inc

08/04/22 4:05 PM

NYSE : NUVB

earnings

Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the second quarter ended June 30, 2022, and provided a business update. As previously announced, this commitment has led us to re-prioritize our...

RHEA-AI

neutral

08/01/22 8:00 AM

NYSE : NUVB

clinical trial

Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program

Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that it will prioritize NUV-868 and development of its novel small molecule DDC platform and discontinue clinical development of NUV-422. Nuvation Bio will intensify its...

RHEA-AI

neutral

07/18/22 7:00 AM

NYSE : NUVB

management

Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer

Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer. “I am honored to join Nuvation Bio and oversee the clinical...

RHEA-AI

positive

06/27/22 7:00 AM

NYSE : NUVB

clinical trial

Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors

Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the Food and Drug Administration has placed a partial clinical hold on the Company’ s Phase 1 dose escalation study of NUV-422 in solid tumors, including high grade glioma, HR+/...

RHEA-AI

neutral

05/09/22 4:05 PM

NYSE : NUVB

earnings

Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update

Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the first quarter ended March 31, 2022, and provided a business update. In the first quarter, we dosed the first patient in our Phase 1 study of NUV-868 in...

RHEA-AI

neutral

02/28/22 4:05 PM

NYSE : NUVB

earnings

Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update. “In 2021, the Nuvation Bio team made significant progress for our...

RHEA-AI

very positive

01/20/22 8:00 AM

Nasdaq, NYSE : RARE, NUVB, SGEN

management

ShouTi Strengthens Board With Appointment of Daniel G. Welch as Chairman

ShouTi Inc., a clinical-stage biopharmaceutical company replacing biologics with world-class small molecule medicines using advanced computational and structure-based technology, today announced that Daniel Welch has been named Chairman of the company’ s board of directors. Mr. Welch is a distinguished life sciences executive,...

RHEA-AI

neutral

01/20/22 7:00 AM

NYSE : NUVB

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advanced Solid Tumors

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the U.S. Food and Drug Administration (FDA) has cleared its

RHEA-AI

neutral

01/10/22 7:00 AM

NYSE : NUVB

Nuvation Bio Provides Corporate Update and Highlights Key 2022 Milestones

David Hung, M.D., founder, president, and chief executive officer, to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022 at 7:30 a.m. ETMultiple trials anticipated to initiate in 2022 as well as additional IND filings -• Phase 2 monotherapy cohorts and

RHEA-AI

very positive

12/15/21 7:00 AM

NYSE : NUVB

Nuvation Bio Receives FDA Fast Track Designation for NUV-422 for the Treatment of High-Grade Gliomas, Including Glioblastoma Multiforme

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast

RHEA-AI

very positive

NUVB Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.nuvationbio.com
Security nameNuvation Bio Inc - Class A
Issue typecs
SectorManufacturing
Sic code2834
Employees36

About Nuvation Bio Inc

Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.